© 2002 by Gut
THERAPY UPDATE
Which 5-ASA?
John Radcliffe Hospital, Oxford OX3 9DU, UK; simon.travis@orh.nhs.uk
Keywords: 5-aminosalicylic acid; ulcerative colitis; Crohn' disease; inflammatory bowel disease
| The first 150 words of the full text of this article appear below. |
When Asacol commands 65% of the UK market, can so many British gastroenterologists be wrong? Possibly. The market leader in France is Pentasa (72%) and is Salofalk in Germany (57%). In Canada it is Asacol (46%). Nevertheless, a Cochrane review of 11 trials involving 1598 patients showed that sulphasalazine was more effective than other 5-aminosalicylic acid (5-ASA) drugs for maintaining remission in ulcerative colitis (odds ratio (OR) 1.29, confidence interval (CI) 1.061.57).1 Diagnosis, disease location, activity, side effect profile, efficacy, and cost all affect the choice of 5-ASA.
5-ASA acts on and is metabolised by intestinal epithelial cells. Consequently, ulcerative colitis (a mucosal disease) is more susceptible to treatment by 5-ASA than transmural Crohn's disease. Mega doses of mesalazine (
4 g/day) may be an initial alternative to steroids for mild-moderately active ulcerative colitis and reduce the risk of relapse after small intestinal (but not colonic) resection for Crohn's disease.2
This article has been cited by other articles:
-
Mansfield, J C
(2003). Which 5-ASA?. Gut
52: 771-771
[Full Text]
eLetters:
Read all eLetters
- Pentasa may not be the optimal 5ASA
- John C Mansfield
- Gut Online, 7 Nov 2002 [Full text]
- Which 5ASA?
- Simon Travis
- Gut Online, 21 Dec 2002 [Full text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
